Loading company…
Rallybio develops therapeutics for rare and severe diseases, aiming first at fetal and neonatal alloimmune thrombocytopenia.
Founded in 2018 and based in Connecticut, US, Rallybio develops small-molecule and protein-based therapies for severe and rare diseases. Its main goal is to prevent prenatal and neonatal alloimmune thrombocytopenia, a rare condition that can cause fatal bleeding in fetuses and infants. Its programs cover maternal fetal blood disorders, complement dysregulation and metabolic disorders. Founders are Jeffrey Fryer, Martin Mackay and Stephen Uden. The company raised a total of USD 275.2 million in funding in 2020 and, as of July 2021, planned to list on Nasdaq under the ticker RLYB.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in